These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38679290)

  • 1. Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma.
    Maciel D; Jansen JP; Klijn SL; Towle K; Dhanda D; Malcolm B; Cope S
    Value Health; 2024 Apr; ():. PubMed ID: 38679290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
    Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
    Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
    Shah N; Mojebi A; Ayers D; Cope S; Dhanasiri S; Davies FE; Hari P; Patel P; Hege K; Dhanda D
    J Comp Eff Res; 2022 Jul; 11(10):737-749. PubMed ID: 35485211
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
    Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
    Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
    J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
    Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
    Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
    Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
    N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
    Ayers D; Cope S; Towle K; Mojebi A; Marshall T; Dhanda D
    BMC Med Res Methodol; 2022 Oct; 22(1):272. PubMed ID: 36243687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
    McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
    Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
    Delforge M; Otero PR; Shah N; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Devlen J; Miera M; Gerould H; Campbell TB; Munshi NC
    Leuk Res; 2023 Jun; 129():107074. PubMed ID: 37087950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
    Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
    Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
    Dima D; Rashid A; Davis JA; Shune L; Abdallah AO; Li H; DeJarnette S; Khouri J; Williams L; Hashmi H; Raza S; McGuirk J; Anwer F; Ahmed N
    Br J Haematol; 2024 Apr; 204(4):1293-1299. PubMed ID: 38263627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
    Anderson LD
    Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
    Minakata D; Ishida T; Ando K; Suzuki R; Tanaka J; Hagiwara S; Ananthakrishnan R; Kuwayama S; Nishio M; Kanda Y; Suzuki K
    Int J Hematol; 2023 May; 117(5):729-737. PubMed ID: 36690910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
    Shah N; Delforge M; San-Miguel J; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Miera M; Williams A; Murphy R; Devlen J; Hege K; Campbell TB; Munshi NC
    Leuk Res; 2022 Sep; 120():106921. PubMed ID: 35930999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.